Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic ...
The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any ...
CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...
Theseus Pharmaceuticals Inc (NASDAQ:THRX) will discontinue enrollment in the ongoing phase 1/2 study and terminate the development of THE-630 in patients with gastrointestinal stromal tumors (GIST).
Theseus struggles to escape toxicity labyrinth as safety signal sinks cancer program and share price
A safety signal has derailed Theseus Pharmaceuticals’ quest to develop a gastrointestinal stromal tumor (GIST) treatment. The dose-limiting toxicity drove the biotech to stop enrollment and end ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful ...
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of ...
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today shared new data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback